A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
N/A
Post-marketing surveillance study to evaluate the real world safety and eff...
Status
Completed
Location
Dong-A University Hospital /ID# 167362
Start Date
2017-08-17
Trial ID
NCT03201718
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
PHASE3
The purpose of this study was to evaluate the effect of treatment with ABT-...
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
N/A
This is an observational, prospective, open-label, single-arm, multicenter,...
Status
Completed
Location
Kantonsspital St. Gallen
Start Date
2017-03-01
Trial ID
NCT03002818
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
N/A
Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial....
Status
Completed
Location
National Taiwan University Hospital, Yun-Lin Branch
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
PHASE3
The purpose of this study was to evaluate the effect of treatment with ABT-...